ES2185897T3 - Uso de 2-carnitinas de alcanoilo para la fabricacion de un medicamento para el tratamiento de enfermedades inflamatorias del intestino. - Google Patents

Uso de 2-carnitinas de alcanoilo para la fabricacion de un medicamento para el tratamiento de enfermedades inflamatorias del intestino.

Info

Publication number
ES2185897T3
ES2185897T3 ES97830270T ES97830270T ES2185897T3 ES 2185897 T3 ES2185897 T3 ES 2185897T3 ES 97830270 T ES97830270 T ES 97830270T ES 97830270 T ES97830270 T ES 97830270T ES 2185897 T3 ES2185897 T3 ES 2185897T3
Authority
ES
Spain
Prior art keywords
treatment
alcanoilo
carnitines
intestine
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97830270T
Other languages
English (en)
Inventor
Claudio Cavazza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of ES2185897T3 publication Critical patent/ES2185897T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0031Rectum, anus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE DESCUBRE EL USO DE ALCANOIL INFERIOR L RA LA PREPARACION DE COMPOSICIONES FARMACEUTICAS (EN PARTICULAR ESPUMAS Y ENEMAS) PARA EL TRATAMIENTO DE ENFERMEDADES INTESTINALES INFLAMATORIAS CRONICAS, EN PARTICULAR COLITIS ULCERATIVA.
ES97830270T 1996-06-06 1997-06-03 Uso de 2-carnitinas de alcanoilo para la fabricacion de un medicamento para el tratamiento de enfermedades inflamatorias del intestino. Expired - Lifetime ES2185897T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT96RM000396A IT1284661B1 (it) 1996-06-06 1996-06-06 Uso di alcanoil l-carnitine nel trattamento terapeutico di malattie infiammatorie croniche intestinali.

Publications (1)

Publication Number Publication Date
ES2185897T3 true ES2185897T3 (es) 2003-05-01

Family

ID=11404269

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97830270T Expired - Lifetime ES2185897T3 (es) 1996-06-06 1997-06-03 Uso de 2-carnitinas de alcanoilo para la fabricacion de un medicamento para el tratamiento de enfermedades inflamatorias del intestino.

Country Status (14)

Country Link
US (2) US6013670A (es)
EP (1) EP0811376B1 (es)
JP (1) JP4171085B2 (es)
KR (1) KR100450293B1 (es)
AT (1) ATE226069T1 (es)
CA (1) CA2206995C (es)
DE (1) DE69716341T2 (es)
DK (1) DK0811376T3 (es)
ES (1) ES2185897T3 (es)
IT (1) IT1284661B1 (es)
MX (1) MX9704150A (es)
PT (1) PT811376E (es)
TW (1) TW585763B (es)
ZA (1) ZA974946B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348495B1 (en) * 1996-06-06 2002-02-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Method for treating celiac disease
EP0972516A1 (en) * 1998-06-25 2000-01-19 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Gastro-intestinal adverse effect-free composition comprising an L-carnitine replacement.
US20010025027A1 (en) * 2000-03-07 2001-09-27 Sonis Stephen T. Inhibition of ceramide for the prevention and treatment of oral mucositis induced by antineoplastic drugs or radiation
JP4104834B2 (ja) * 2001-04-13 2008-06-18 株式会社東芝 Mis型電界効果トランジスタの製造方法
ITRM20040168A1 (it) * 2004-04-01 2004-07-01 Sigma Tau Ind Farmaceuti Composizione a rilascio modificato ph dipendente.
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
CN100421648C (zh) * 2006-08-15 2008-10-01 苏州市立医院 氢化考的松灌肠剂及其制备方法
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537772A (en) * 1984-05-02 1985-08-27 Merck & Co., Inc. Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines
IT1181682B (it) * 1985-06-11 1987-09-30 Sigma Tau Ind Farmaceuti Impiego di alcanoil l-carnitine per il trattamento terapeutico del parkinsonismo idiopatico o indotto
IT1258370B (it) * 1992-03-02 1996-02-26 Sigma Tau Ind Farmaceuti Esteri della l-carnitina e di acil l-carnitine dotati di attivita' miorilassante selettiva sull'apparato gastro-intestinale e composizioni farmaceutiche che li contengono.
IT1254314B (it) * 1992-03-27 1995-09-14 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.
IT1277898B1 (it) * 1995-08-03 1997-11-12 Mendes Srl Uso di amminoacidi basici, di acil derivati di amminoacidi basici e di loro sali farmaceuticamente accettabili per la profilassi di malattie
IT1283967B1 (it) * 1996-03-29 1998-05-07 Sigma Tau Ind Farmaceuti Uso di l-carnitina o derivati della l-carnitina ed antiossidanti nella prevenzione e trattamento di patologie derivanti da danni ossidativi

Also Published As

Publication number Publication date
JPH1059845A (ja) 1998-03-03
EP0811376B1 (en) 2002-10-16
PT811376E (pt) 2003-03-31
TW585763B (en) 2004-05-01
EP0811376A1 (en) 1997-12-10
US6013670A (en) 2000-01-11
KR980000444A (ko) 1998-03-30
ITRM960396A1 (it) 1997-12-06
ATE226069T1 (de) 2002-11-15
DE69716341D1 (de) 2002-11-21
KR100450293B1 (ko) 2004-11-20
IT1284661B1 (it) 1998-05-21
CA2206995A1 (en) 1997-12-06
ITRM960396A0 (it) 1996-06-06
CA2206995C (en) 2007-10-30
DK0811376T3 (da) 2003-03-10
US6143785A (en) 2000-11-07
ZA974946B (en) 1997-12-18
JP4171085B2 (ja) 2008-10-22
DE69716341T2 (de) 2003-06-05
MX9704150A (es) 1997-12-31

Similar Documents

Publication Publication Date Title
SE9703226D0 (sv) New pharmaceutical composition
ES2188929T3 (es) Analogos 2-peptidicos de tipo glucagon.
ATE125445T1 (de) Orale zusammensetzung für die behandlung intestinaler entzündlicher krankheiten.
AR012614A1 (es) Una composicion farmaceutica para la fabricacion de un medicamento destinado para el tratamiento de una infeccion viral susceptible de tratamientocon interferon alfa, un metodo para la fabricacion de un medicamento, el uso de peg12000-ifn alfa para la fabricacion de un medicamento
AR016798A1 (es) Uso de una cepa de lactobacillus para la elaboracion de un medicamento
NO20060185L (no) Anvendelse av isomalt (blanding av 1,6 GPS og 1,1 GPM) som prebiotikum blant annet for fremstilling av et legemiddel for behandling av tarmsykdommer
ES2172533T3 (es) Uso de nonapeptidos y decapeptidos para la preparacion de un medicamento para combatir el sida.
ES2188586T3 (es) Utilizacion de inhibidores del complemento para la preparacion de un medicamento para la profilaxis y terapia de enfermedades inflamatorias intestinales y de la piel, asi como purpura.
AR013612A1 (es) Colostrinina y usos de la misma para la manufactura de un medicamento, una composicion farmaceutica que la comprende, uso de la misma como suplemento dedieta, un suplemento de dieta, un nonapeptido, el uso del mismo para la manufactura de un medicamento, composicion farmaceutica y metodo para prepar
CO5680109A1 (es) Compuestos para el tratamiento de la disfuncion sexual femenina
AR004510A1 (es) Composiciones que comprenden amoxicilina y clavulanato, procedimientos para su preparacion y el uso de las composiciones para la fabricacion de unmedicamento
ES2185897T3 (es) Uso de 2-carnitinas de alcanoilo para la fabricacion de un medicamento para el tratamiento de enfermedades inflamatorias del intestino.
BR9709838A (pt) Regime de administração que fornece um perfil de plasma no sangue de um inibidor de h+,k+-atpase composição farmacêutica oral uso da mesma e de inibidor h+,k+-atpase e processos para melhorar a inibição de secreção de ácido gástrico e o efeito terapêutico no tratamento de perturbações gastrintestinais e para receber um perfil estendido de plasma de um inibidor de h+,k+-atpase
AR019699A1 (es) Composicion farmaceutica para el tratamiento de disfuncion de la evacuacion y uso de la misma para la preparacion de un agente terapeutico
DE69615583D1 (de) Örtliche arzneistoffabgabe in tieferen magendarmtraktabschnitten
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
DK0421541T3 (da) Tabletstruktur, som kan deles
AR034920A1 (es) Metodos para el tratamiento de enfermedades intestinales inflamatorias
NO20034417D0 (no) Engangs vaginalkanyle for samtidig administrasjon av medikamenter i ulike former
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
DE69819922D1 (de) 2-Amino-6-methyl-7-acetyl-tetralin und pharmazeutische Zusammensetzungen zur Vorbeugung und therapeutischen Behandlung von entzündlichen und/oder Autoimmunkrankheiten
MX9301879A (es) Medicamento para el tratamiento de la inflamacion de las vias respiratorias
ES2175582T3 (es) Cromanos sustituidos con sulfonamida, procedimiento para su preparacion, su utilizacion como medicamento, asi como preparados farmaceuticos que los contienen.
CO4790092A1 (es) Granisetron para tratamiento de la diarrea
HRP20040165B1 (en) Citalopram for the treatment of elevated blood pressure